icon-    folder.gif   Conference Reports for NATAP  
  (APASL) 24th Conference of the Asian Pacific
Association for the Study of the Liver
12-15 March, 2014
Brisbane, Australia
Back grey_arrow_rt.gif
Simeprevir with Peginterferon/Ribavirin for Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Treatment-Experienced Patients: Interim Results of a Phase III Rollover Trial
  Reported by Jules Levin
APASL 2014 March 12-15 Brisbane, Australia
Ed Gane,1 Jacob George,2 Peter Ferenci,3 Rafael Esteban,4 Henk Reesink,5 Mike W Fried,6 Edwin DeJesus,7 Maribel Rodriguez Torres,8
Wilbert Van Duijnhoven,9 Umesh Shukla,9 Ronald Kalmeijer,9 Bart Fevery,9 Maria Beumont-Mauviel,9 Guy De La Rosa,10 Wolfgang Jessner9
1University of Auckland, New Zealand; 2Westmead Hospital, University of Sydney, Australia; 3Medical University of Vienna, Austria; 4Hospital Universitario Val d'Hebron, Universidad Autonoma de Barcelona, Spain; 5University of Amsterdam, The Netherlands; 6University of North Carolina, USA; 7Orlando Immunology Center, USA; 8Fundacion de Investigacion de Diego, San Juan, Puerto Rico; 9Janssen Infectious Diseases, Beerse, Belgium/Titusville, NJ, USA; 10Janssen Global Services, Titusville, NJ, USA